Woburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.Chief Executive Officer Ms. Katie Field ...

Core Insights - iSpecimen Inc. has achieved significant milestones that showcase the strength and reliability of its biospecimen sourcing network [1] Group 1: Company Achievements - iSpecimen has successfully collected 500 influenza swab samples in a few weeks to support customer research, demonstrating its responsiveness to time-sensitive needs [2] - The company maintains a consistent supply of cerebrospinal fluid (CSF) and is experiencing increased client interest in a broader range of specimen types, indicating a growing demand for diverse biospecimen sourcing [3] - Customer feedback highlights iSpecimen's commitment to quality, with one client expressing satisfaction with the quality and documentation of urine specimens received [4] Group 2: Commitment to Quality - iSpecimen's accomplishments reflect its ongoing dedication to providing timely access to well-documented biospecimens that support critical research and scientific advancement [5] - The company utilizes proprietary, cloud-based technology to connect scientists with healthcare providers, facilitating intuitive searches for specimens across a federated partner network [6]

Financial Data and Key Metrics Changes - The annual meeting was held virtually, and a quorum was not present, preventing the company from conducting business or discussing financial data [3][4]. Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting due to the lack of quorum [3][4]. Market Data and Key Metrics Changes - There were no updates on market data or key metrics as the meeting was adjourned without conducting any business [3][4]. Company Strategy and Development Direction - The company did not present any strategic updates or development directions during the meeting due to the adjournment [3][4]. Management's Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook as the meeting was unable to proceed [3][4]. Other Important Information - The company will announce the date and manner of the reconvened annual meeting to allow stockholders to submit proxies and achieve a quorum [4]. Q&A Session Summary - There were no questions or answers during the meeting as it was adjourned before any discussions could take place [3][4].

Financial Data and Key Metrics Changes - The annual meeting was held virtually, and a quorum was not present, preventing the company from conducting business or discussing financial data [3][4]. Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting due to the lack of quorum [3][4]. Market Data and Key Metrics Changes - There were no updates on market data or key metrics as the meeting was adjourned without conducting any business [3][4]. Company Strategy and Development Direction - The company did not present any strategic updates or development directions during the meeting due to the adjournment [3][4]. Management's Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook as the meeting was unable to proceed [3][4]. Other Important Information - The company will announce the date and manner of the reconvened annual meeting to allow stockholders to submit proxies and achieve a quorum [4]. Q&A Session All Questions and Answers - No questions or answers were recorded as the meeting was adjourned before any discussions could take place [3][4].

Financial Data and Key Metrics Changes - The annual meeting was held virtually, and a quorum was not present, preventing the company from conducting business or discussing financial data [3][4]. Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting due to the lack of quorum [3][4]. Market Data and Key Metrics Changes - There were no updates on market data or key metrics as the meeting was adjourned without conducting any business [3][4]. Company Strategy and Development Direction - The company did not present any strategic updates or development directions during the meeting due to the adjournment [3][4]. Management's Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook as the meeting was unable to proceed [3][4]. Other Important Information - The company will announce the date and manner of the reconvened annual meeting to allow stockholders to submit proxies and achieve a quorum [4]. Q&A Session Summary - There were no questions or answers during the meeting as it was adjourned before any business could be conducted [3][4].

MANHATTAN, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co., a Manhattan-headquartered investment bank and broker-dealer, today announced that it acted as the exclusive placement agent in connection with iSpecimen Inc.’s (Nasdaq: ISPC) private placement, raising approximately $5.5 million in gross proceeds before fees and expenses. The transaction reflects continued capital markets interest in differentiated healthcare technology platforms that support medical research and discovery. iSpecimen oper ...

Core Viewpoint - iSpecimen Inc. has entered into a securities purchase agreement with accredited investors, aiming to raise approximately $5.5 million through the issuance of Series C Convertible Preferred Stock [1][2][3] Group 1: Offering Details - The company will issue 6,875 shares of Series C Convertible Preferred Stock at a price of $800 per share, convertible into common stock at a conversion price of 85% of the closing price prior to each conversion date [2][3] - The offering is expected to close on or about December 31, 2025, pending customary closing conditions [3] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for marketing, working capital, and general corporate purposes [3] Group 3: Regulatory Information - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Act or applicable state laws, limiting their sale to accredited investors [4]

As filed with the Securities and Exchange Commission on December 19, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 8 Cabot Road, Suite 1800 Woburn, MA 081 ...

Financial Performance - Revenue decreased by approximately $2,555,000, or 96%, from approximately $2,662,000 for the three months ended September 30, 2024, to approximately $107,000 for the three months ended September 30, 2025[208]. - Specimen count decreased by 8,181, or approximately 97%, from 8,461 specimens in the three months ended September 30, 2024, to 280 specimens in the three months ended September 30, 2025[208]. - Revenue decreased by approximately $5,938,000, or 76%, from approximately $7,816,000 for the nine months ended September 30, 2024 to approximately $1,877,000 for the nine months ended September 30, 2025, primarily due to a decrease of 14,498 specimens, or approximately 74%[219]. - Cost of revenue decreased by approximately $2,673,000, or 67%, from approximately $3,979,000 for the nine months ended September 30, 2024 to approximately $1,306,000 for the nine months ended September 30, 2025, attributed to a 74% decrease in the number of specimens delivered[221]. - Net loss increased by approximately $1,340,795, or 93%, from $1,439,853 for the three months ended September 30, 2024, to $2,780,648 for the three months ended September 30, 2025[207]. Operating Expenses - Total operating expenses decreased by approximately $1,430,526, or 33%, from $4,367,340 for the three months ended September 30, 2024, to $2,936,814 for the three months ended September 30, 2025[207]. - Total operating expenses decreased by approximately $6,535,923, or 44%, from approximately $14,703,197 for the nine months ended September 30, 2024 to approximately $8,167,274 for the nine months ended September 30, 2025[218]. - General and administrative expenses decreased by approximately $1,481,000, or 37%, from approximately $4,052,000 for the nine months ended September 30, 2024 to approximately $2,571,000 for the nine months ended September 30, 2025[227]. - Fulfillment costs decreased by approximately $597,000, or 46%, from approximately $1,293,000 for the nine months ended September 30, 2024 to approximately $696,000 for the nine months ended September 30, 2025[226]. - Technology expenses decreased by approximately $946,000, or 37%, from approximately $2,579,000 for the nine months ended September 30, 2024 to approximately $1,633,000 for the nine months ended September 30, 2025[222]. Cash Flow and Financing - Cash and cash equivalents increased by approximately $904,350, or 48%, from approximately $1,878,408 as of December 31, 2024 to approximately $2,782,758 as of September 30, 2025[229]. - Net cash flows used in operating activities decreased by approximately $1,367,347, or 29%, from approximately $4,691,032 for the nine months ended September 30, 2024 to approximately $3,323,685 for the nine months ended September 30, 2025[229]. - Net cash provided by financing activities was approximately $5,228,000 for the nine months ended September 30, 2025, including $1,750,000 from PIPE financing and $4,000,000 from Underwritten financing[239]. Market and Operational Challenges - iSpecimen Inc. faced operational challenges due to the Russian-Ukrainian war, impacting approximately $1 million in purchase orders and leading to delays and margin reductions[185]. - Inflation has negatively impacted employee salaries and supply costs, although the costs of specimens have not been significantly affected due to long-term vendor contracts[242][243]. - The company has not experienced material supply chain issues affecting transportation, allowing timely deliveries during the nine months ended September 30, 2025[241]. Strategic Initiatives - iSpecimen Marketplace automates the procurement process, allowing researchers to efficiently find and manage specimens, enhancing operational efficiency for both researchers and biospecimen providers[159][161]. - The company is focused on enhancing pricing strategies and operational efficiencies to address current market conditions and improve liquidity[183][184]. - The company intends to rely on exemptions provided by the JOBS Act, remaining an "emerging growth company" until certain revenue or debt thresholds are met[248]. Stock and Securities - A reverse stock split of 1-for-20 was approved and became effective on September 13, 2024, allowing the company to regain compliance with Nasdaq listing requirements[171][172]. - The company raised gross proceeds of $4,998,464 from a public offering on October 31, 2024, with net proceeds of approximately $4,632,275 after offering costs[176][177]. - The company generated gross proceeds of $1,749,998 from a private placement on July 31, 2025, with net proceeds of approximately $1,649,998 after offering costs[166][167]. - The company issued 199,004 shares under an ATM agreement for gross proceeds of approximately $1,494,000 during the year ended December 31, 2024, resulting in net proceeds of approximately $1,239,000 after costs[168]. - iSpecimen Inc. entered into a Note Purchase Agreement for a loan of $1,000,000 with an interest rate of 18% per annum, which was fully paid off by October 31, 2024[174][175].

As filed with the Securities and Exchange Commission on October 6, 2025 Registration No. 333-289725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 27-0480143 (IRS Employer Identification No.) 8 Cabot Road, ...